CENTOGENE (CNTG) Price to Earnings Ratio

Centogene N.V. (CNTG) management is betting on monetizing a colossal array of genetic data and collaborating with drug developers. The business relies on the stable humanitarian status of biomedicine, which offsets external political shocks. Leading positions in the diagnosis of orphan pathologies provide the company with exceptional protection against competitors. This price chart, confirming the market valuation, shows a P/E ratio of -0.20.

CNTG Centogene NV: Price to Earnings Ratio in the range 07/04/2022 - 08/10/2024

Analytical breakdowns for Centogene N.V.

- price and consensus price forecast:

Stock Price CENTOGENE, N.V.|CNTG - Price Target Chart

- market capitalization details:

Market Value CENTOGENE N.V.|CNTG - Real Price to Acquire Entire Company

- book capitalization information:

Net Asset Value per Share CENTOGENE|CNTG - Company Book Value|Market Capitalization to Book Value centogene.com|CNTG - Company Total Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

CNTG - Net Income|Future Net Profit Centogene N.V.|CNTG - Price to Earnings Ratio|Projected Price to Earnings Ratio Centogene NV|CNTG - PEG Multiple|Enterprise Value to EBITDA Multiple CENTOGENE N.V.|CNTG - Operating profit EBITDA|Net earnings per one share for the last twelve months CENTOGENE|CNTG - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months centogene.com|CNTG - Earnings growth in current year|Expected net earnings per share growth next year Centogene N.V.

Summary company analysis:CNTG CENTOGENE N.V.

Stable demand for genetic diagnostics of rare pathologies makes the Centogene N.V. (CNTG) business a defensive asset. Mathematically, this is reflected in the ratio of market capitalization to net profit. This coefficient measures the cost of one ruble of profit, linking stock quotes to actual financial results. Low values may signal undervaluation or hidden debt risks. By analyzing the price-to-earnings ratio dynamics, an investor assesses market expectations regarding the company's partnerships with pharma behemoths.

Key competitors